CoChat

Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease

Open access
Luo, Shen, Ma, Chi, Zhu, Ming-Qin, Ju, Wei-Na, Yang, Yu, Wang, Xu · 2020 · Frontiers in Cellular Neuroscience
Cited by 109

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Neurodegenerative diseases are characterized by chronic progressive degeneration of the structure and function of the nervous system, which brings an enormous burden on patients, their families, and society. It is difficult to make early diagnosis, resulting from the insidious onset and progressive development of neurodegenerative diseases. The drugs on the market cannot cross the blood-brain barrier (BBB) effectively, which leads to unfavorable prognosis and less effective treatments. Therefore, there is an urgent demand to develop a novel detection method and therapeutic strategies. Recently, nanomedicine has aroused considerable attention for diagnosis and therapy of central nervous system (CNS) diseases. Nanoparticles integrate targeting, imaging, and therapy in one system and facilitate the entry of drug molecules across the blood-brain barrier, offering new hope to patients. In this review, we summarize the application of iron oxide nanoparticles (IONPs) in the diagnosis and treatment of neurodegenerative disease, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). We focus on IONPs as magnetic resonance imaging (MRI) contrast agents (CAs) and drug carriers in AD. What most neurodegenerative diseases have in common is that hall marker lesions are represented by protein aggregates (Soto and Pritzkow, 2018). These diseases are of unknown etiology and unfavorable prognosis, and the treatments toward them are less effective (Soto and Pritzkow, 2018). Such diseases usually develop in aged people, and early clinical manifestations are atypical, resulting in difficulty in early diagnosis. Recently, nanomedicine has aroused considerable attention for therapy and diagnosis of CNS diseases because it integrates targeting, imaging, and therapy in one system (Gupta et al., 2019). In this review article, we first introduce the neurodegenerative diseases and commonly used MRI CAs. Then we review the application of IONPs in the diagnosis and treatment of neurodegenerative diseases with the purpose of assisting early theranostics (therapy and diagnosis).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fncel.2020.00021

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 59

  1. Akilo, 2016, AN in vitro evaluation of a carmustine-loaded Nano-co-Plex for potential magnetic-targeted intranasal delivery to the brain, Int. J. Pharm., 500, 196, 10.1016/j.ijpharm.2016.01.043 · DOI
  2. André, 2017, Validation by magnetic resonance imaging of the diagnostic potential of a heptapeptide-functionalized imaging probe targeted to amyloid-beta and able to cross the blood-brain barrier, J. Alzheimers Dis., 60, 1547, 10.3233/jad-170563 · DOI
  3. Ansciaux, 2015, In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: toward earlier diagnosis of Alzheimer’s disease by molecular imaging, Contrast Media Mol. Imaging, 10, 211, 10.1002/cmmi.1626 · DOI · Paper page
  4. Anwar, 2014, Synthesis and in vitro localization study of curcumin-loaded SPIONs in a micro capillary for simulating a targeted drug delivery system, Int. J. Pharm., 468, 158, 10.1016/j.ijpharm.2014.04.038 · DOI
  5. Balestrino, 2019, Parkinson disease, Eur. J. Neurol., 10.1111/ene.14108 · DOI · Paper page
  6. Baloh, 2018, Stem cell transplantation for amyotrophic lateral sclerosis, Curr. Opin. Neurol., 31, 655, 10.1097/WCO.0000000000000598 · DOI
  7. Bigini, 2012, Longitudinal tracking of human fetal cells labeled with super paramagnetic iron oxide nanoparticles in the brain of mice with motor neuron disease, PLoS One, 7, e32326, 10.1371/journal.pone.0032326 · DOI
  8. Brambilla, 2011, Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues, Nanomedicine, 7, 521, 10.1016/j.nano.2011.03.008 · DOI · Paper page
  9. Busquets, 2014, Potential applications of magnetic particles to detect and treat Alzheimer’s disease, Nanoscale Res. Lett., 9, 538, 10.1186/1556-276x-9-538 · DOI · Paper page
  10. Canzi, 2012, Human skeletal muscle stem cell antiinflammatory activity ameliorates clinical outcome in amyotrophic lateral sclerosis models, Mol. Med., 18, 401, 10.2119/molmed.2011.00123 · doi:10.2119/molmed.2011.00123
  11. Chamberlain, 2009, Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer’s disease, Magn. Reson. Med., 61, 1158, 10.1002/mrm.21951 · DOI · Paper page
  12. Chandra, 2019, Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer’s disease and mild cognitive impairment, Hum. Brain Mapp., 40, 5424, 10.1002/hbm.24782 · DOI · Paper page
  13. Chen, 2019, Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric Aβ and tau species, Front. Neurosci., 13, 659, 10.3389/fnins.2019.00659 · DOI · Paper page
  14. Cheng, 2015, Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer’s disease mice using magnetic resonance imaging (MRI), Biomaterials, 44, 155, 10.1016/j.biomaterials.2014.12.005 · DOI · Paper page
  15. Chung, 2018, Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson’s disease, Nanoscale, 10, 2998, 10.1039/c7nr06976f · DOI
  16. Corbett, 2012, New and emerging treatments for Alzheimer’s disease, Expert Rev. Neurother., 12, 535, 10.1586/ern.12.43 · DOI · Paper page
  17. De, 2011, Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications, Adv. Drug Deliv. Rev., 63, 1282, 10.1016/j.addr.2011.07.001 · DOI
  18. Dulińska-Litewka, 2019, Superparamagnetic iron oxide nanoparticles-current and prospective medical applications, Materials (Basel), 12, E617, 10.3390/ma12040617 · DOI · Paper page
  19. Fernández, 2018, Functionalization and characterization of magnetic nanoparticles for the detection of ferritin accumulation in Alzheimer’s disease, ACS Chem. Neurosci., 9, 912, 10.1021/acschemneuro.7b00260 · DOI · Paper page
  20. Gagliardi, 2019, Diagnostic and prognostic role of blood and cerebrospinal fluid and blood neurofilaments in amyotrophic lateral sclerosis: a review of the literature, Int. J. Mol. Sci., 20, E4152, 10.3390/ijms20174152 · DOI
  21. Giagkou, 2018, Therapeutic management of the overlapping syndromes of atypical Parkinsonism, CNS Drugs, 32, 827, 10.1007/s40263-018-0551-3 · DOI
  22. Glat, 2013, Age-dependent effects of microglial inhibition in vivo on Alzheimer’s disease neuropathology using bioactive-conjugated iron oxide nanoparticles, J. Nanobiotechnology, 11, 32, 10.1186/1477-3155-11-32 · DOI · Paper page
  23. Gupta, 2019, Nanoparticle formulations in the diagnosis and therapy of Alzheimer’s disease, Int. J. Biol. Macromol., 130, 515, 10.1016/j.ijbiomac.2019.02.156 · DOI · Paper page
  24. Ikenaka, 2019, Lipids as trans-acting effectors for alpha-synuclein in the pathogenesis of Parkinson’s disease, Front. Neurosci., 13, 693, 10.3389/fnins.2019.00693 · DOI
  25. Javdani, 2019, Effect of superparamagnetic nanoparticles coated with various electric charges on α-synuclein and β-amyloid proteins fibrillation process, Int. J. Nanomedicine, 14, 799, 10.2147/ijn.s190354 · DOI
  26. Jiang, 2017, Detection of Aβ oligomers based on magnetic-field-assisted separation of aptamer-functionalized Fe3O4 magnetic nanoparticles and BaYF5:Yb,Er nanoparticles as upconversion fluorescence labels, Talanta, 170, 350, 10.1016/j.talanta.2017.04.021 · DOI
  27. Jirak, 2019, Fluorine polymer probes for magnetic resonance imaging: quo vadis?, MAGMA, 32, 173, 10.1007/s10334-018-0724-6 · DOI
  28. Katebi, 2019, Superparamagnetic iron oxide nanoparticles combined with NGF and quercetin promote neuronal branching morphogenesis of PC12 cells, Int. J. Nanomedicine, 14, 2157, 10.2147/ijn.s191878 · DOI · Paper page
  29. Klohs, 2012, Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcAβ mice, J. Neurosci., 32, 1705, 10.1523/jneurosci.5626-11.2012 · DOI · Paper page
  30. Kong, 2012, Magnetic targeting of nanoparticles across the intact blood-brain barrier, J. Control Release, 164, 49, 10.1016/j.jconrel.2012.09.021 · DOI · Paper page
  31. Kouyoumdjian, 2013, Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity, ACS Chem. Neurosci., 4, 575, 10.1021/cn3002015 · DOI · Paper page
  32. Li, 2019, Improving sensitivity and specificity of amyloid-β peptide and tau protein detection with anti-biofouling magnetic nanoparticles for liquid biopsy of Alzheimer’s disease, ACS Biomater. Sci. Eng., 5, 3595, 10.1021/acsbiomaterials.9b00086 · DOI · Paper page
  33. Ling, 2013, Chemical design of biocompatible iron oxide nanoparticles for medical applications, Small, 9, 1450, 10.1002/smll.201202111 · DOI · Paper page
  34. Mahmoudi, 2013, Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid β protein fibrillation in solution, ACS Chem. Neurosci., 4, 475, 10.1021/cn300196n · DOI · Paper page
  35. Marasini, 2020, Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 12, e1580, 10.1002/wnan.1580 · DOI
  36. Mirsadeghi, 2016, Effect of PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) under magnetic field on amyloid β fibrillation process, Mater. Sci. Eng. C Mater. Biol. Appl., 59, 390, 10.1016/j.msec.2015.10.026 · DOI
  37. Niu, 2017, Inhibition by multifunctional magnetic nanoparticles loaded with α-synuclein RNAi plasmid in a Parkinson’s disease model, Theranostics, 7, 344, 10.7150/thno.16562 · DOI · Paper page
  38. Petiet, 2012, Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer’s transgenic mice, Neurobiol. Aging, 33, 1533, 10.1016/j.neurobiolaging.2011.03.009 · DOI
  39. Pillai, 2018, Rapidly progressive Alzheimer’s disease in two distinct autopsy cohorts, J. Alzheimers Dis., 64, 973, 10.3233/jad-180155 · DOI
  40. Poduslo, 2002, Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging, Neurobiol. Dis., 11, 315, 10.1006/nbdi.2002.0550 · DOI · Paper page
  41. Ramos-Gómez, 2015, Optimization of the magnetic labeling of human neural stem cells and MRI visualization in the hemiparkinsonian rat brain, J. Nanobiotechnology, 13, 20, 10.1186/s12951-015-0078-4 · DOI
  42. Rashid, 2016, Cyclen-based Gd3+ complexes as MRI contrast agents: relaxivity enhancement and ligand design, Bioorg. Med. Chem., 24, 5663, 10.1016/j.bmc.2016.09.069 · DOI
  43. Rotman, 2011, Pre-clinical optical imaging and MRI for drug development in Alzheimer’s disease, Drug Discov. Today Technol., 8, e117, 10.1016/j.ddtec.2011.11.005 · DOI
  44. Sachdeva, 2015, Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: behavioral and biochemical evidence, Eur. J. Pharmacol., 747, 132, 10.1016/j.ejphar.2014.11.014 · DOI
  45. Salama, 2017, Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson’s disease, Exp. Ther. Med., 13, 976, 10.3892/etm.2017.4073 · DOI
  46. Sibov, 2014, Umbilical cord mesenchymal stem cells labeled with multimodal iron oxide nanoparticles with fluorescent and magnetic properties: application for in vivo cell tracking, Int. J. Nanomedicine, 9, 337, 10.2147/ijn.s53299 · DOI
  47. Sillerud, 2013, SPION-enhanced magnetic resonance imaging of Alzheimer’s disease plaques in AβPP/PS-1 transgenic mouse brain, J. Alzheimers Dis., 34, 349, 10.3233/jad-121171 · DOI · Paper page
  48. Skaat, 2013, Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-beta fibrils, Int. J. Nanomedicine, 8, 4063, 10.2147/ijn.s52833 · DOI
  49. Sonawane, 2019, Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer’s disease, ACS Omega, 4, 12833, 10.1021/acsomega.9b01411 · DOI · Paper page
  50. Sugaya, 2018, Stem cell therapies for neurodegenerative diseases, Adv. Exp. Med. Biol., 1056, 61, 10.1007/978-3-319-74470-4_5 · DOI
  51. Sun, 2016, Biodistribution of negatively charged iron oxide nanoparticles (IONPs) in mice and enhanced brain delivery using lysophosphatidic acid (LPA), Nanomedicine, 12, 1775, 10.1016/j.nano.2016.04.008 · DOI
  52. Tafoya, 2017, Superparamagnetic nanoparticle-enhanced MRI of Alzheimer’s disease plaques and activated microglia in 3X transgenic mouse brains: contrast optimization, J. Magn. Reson. Imaging, 46, 574, 10.1002/jmri.25563 · DOI
  53. Teleanu, 2019, Nanomaterials for drug delivery to the central nervous system, Nanomaterials (Basel), 9, E371, 10.3390/nano9030371 · DOI · Paper page
  54. Thomsen, 2015, Targeted drug delivery to the brain using magnetic nanoparticles, Ther Deliv, 6, 1145, 10.4155/tde.15.56 · DOI · Paper page
  55. Yang, Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer’s disease in vitro, ACS Chem. Neurosci., 2, 500, 10.1021/cn200028j · DOI · Paper page
  56. Yang, 2016, Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles, J. Nanobiotechnology, 14, 41, 10.1186/s12951-016-0198-5 · DOI
  57. Yarjanli, 2017, Iron oxide nanoparticles may damage to the neural tissue through iron accumulation, oxidative stress and protein aggregation, BMC Neurosci., 18, 51, 10.1186/s12868-017-0369-9 · DOI · Paper page
  58. Zhang, 2015, The detection of beta-amyloid plaques in an Alzheimer’s disease rat model with DDNP-SPIO, Clin. Radiol., 70, 74, 10.1016/j.crad.2014.09.019 · DOI
  59. Zhou, 2014, Synthesis of superparamagnetic iron oxide nanoparticles coated with a DDNP-carboxyl derivative for in vitro magnetic resonance imaging of Alzheimer’s disease, Mater. Sci. Eng. C Mater. Biol. Appl., 37, 348, 10.1016/j.msec.2014.01.005 · DOI

Cited by

See all 109

Metadata

Authors
Luo, S., Ma, C., Zhu, M.-Q., Ju, W.-N., Yang, Y., & Wang, X.
Venue
Frontiers in Cellular Neuroscience
Published
2020-02-28
Volume
14
Pages
21-21
ISSN
1662-5102 (ISSN-L)
OpenAlex
W3008979652
Cited by
109
References
17
FWCI
3.23
Type
journal article
Language
en
Open access
gold
Funders
National Natural Science Foundation of China (81901083)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease. https://app.cochat.ai/papers/10.3389/fncel.2020.00021
The paper
Luo, S., Ma, C., Zhu, M.-Q., Ju, W.-N., Yang, Y., & Wang, X. (2020). Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2020.00021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.